Implications of the PEGASUS-TIMI 54 trial for US clinical practice.

Bradley, Steven M; Hess, Gregory P; Stewart, Patrick; Armstrong, Ehrin J; Farmer, Steven A; Wasfy, Jason H; Valle, Javier Alfonso; Sandhu, Amneet; Maddox, Thomas M

Bradley, Steven M; Hess, Gregory P; Stewart, Patrick; Armstrong, Ehrin J; Farmer, Steven A; Wasfy, Jason H; Valle, Javier Alfonso; Sandhu, Amneet; Maddox, Thomas M.

Afiliação

Bradley SM; Minneapolis Heart Institute, Minneapolis, Minnesota, USA.
Hess GP; VA Eastern Colorado and University of Colorado, Colorado, USA.
Stewart P; Department of Medicine, VA Eastern Colorado Health Care System, Denver, Colorado, USA.
Armstrong EJ; Symphony Health, Conshohocken, Pennsylvania, USA.
Farmer SA; LDI University of Pennsylvania, Philadelphia PA, USA.
Wasfy JH; Symphony Health, Conshohocken, Pennsylvania, USA.
Valle JA; Department of Medicine, VA Eastern Colorado Health Care System, Denver, Colorado, USA.
Sandhu A; Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Maddox TM; George Washington University, Washington, DC, USA.

Open Heart ; 4(1): e000580, 2017.

Article em En | MEDLINE | ID: mdl-28674626

Palavras-chave

P2Y12; cost; myocardial infarction; secondary prevention

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Idioma: En Revista: Open Heart Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google